In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Execs On The Move, February 2020

Executive Summary

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

You may also be interested in...



Executives On The Move: I-Mab Brings On An Amgen Communications Exec And SciTech Picks A CMO, Along With A Promotion At Urovant Sciences

I-Mab Biopharma, a Chinese firm focusing on biologics for cancer and immune diseases, brings on an Amgen exec as global head, corporate communications, and SciTech Development, with its proprietary nano-delivery system, adds a new CMO. Plus, urologic therapies company Urovant Sciences promotes a director to CEO.

Executives On The Move: BMS Taps Barclays Exec For Strategy Spot, Epizyme Selects Science Chief And A Board Election At ADC Therapeutics

Bristol-Myers Squibb taps Barclays chair of global life sciences as it EVP, strategy and business development, and cancer therapeutics firm Epizyme Inc. selects a chief scientific officer. At ADC Therapeutics, an oncology drug development company, a new chairman is elected.

Executives On The Move: Global Aesthetics Head Exits Allergan for Merz, C-Level Commercial Changes at Flexion And Karyopharm

Merz Pharma Group’s Merz Aesthetics welcomes former Allergan exec as new chief scientific officer. Meanwhile, a chief commercial officer is appointed at Flexion Therapeutics, developer of treatments for musculoskeletal conditions, and at Karyopharm Therapeutics, an oncology-focused pharma.

Topics

UsernamePublicRestriction

Register

IV124446

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel